Dihydrobenzofuran and indene analogs as ganglion inhibitors

Selective allosteric inhibitors of cardiac myosin, targeting myocardial segments, improve therapeutic outcomes for HCM and HFpEF by enhancing safety and efficacy while minimizing adverse effects.

JP2026113610APending Publication Date: 2026-07-07CYTOKINETICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
CYTOKINETICS INC
Filing Date
2026-04-02
Publication Date
2026-07-07

AI Technical Summary

Technical Problem

Current drugs targeting myocardial ganglia, such as inotropes, exhibit poor selectivity for cardiac tissue, leading to adverse effects like cell damage, relaxation abnormalities, and arrhythmic side effects, limiting their effectiveness in treating conditions like hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF.

Method used

Development of selective allosteric inhibitors of cardiac myosin, specifically heterocyclic compounds that target myocardial segments, providing improved therapeutic indices with less impact on cardiac relaxation and better safety profiles.

Benefits of technology

These compounds offer a broader therapeutic index, reduced impact on cardiac relaxation, and enhanced pharmacokinetics, addressing the limitations of existing drugs in treating HCM and HFpEF.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026113610000001
    Figure 2026113610000001
  • Figure 2026113610000002
    Figure 2026113610000002
  • Figure 2026113610000003
    Figure 2026113610000003
Patent Text Reader

Abstract

To provide a method for treating a disease. [Solution] The formula provided is: (I): JPEG2026113610000400.jpg1851 is a compound or a pharmaceutically acceptable salt thereof, where A, Z, B, R 1 , R 2 , R 3 G1, G2, and G3 are as defined herein. Also provided are pharmaceutically acceptable compositions comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compound of formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treating cardiac disease by inhibition of the myocardial ganglia.
Need to check novelty before this filing date? Find Prior Art